In the phase 3 OCEANIC-STROKE trial, asundexian significantly reduced recurrent ischemic stroke risk compared with placebo without significantly increasing major bleeding. The Food and Drug ...
Primary care practitioners serve a critical role in optimizing clinical outcomes for adults with T2DM by evaluating underlying mechanisms, treatment efficacy, medication safety profiles, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results